Correlation Between Neurocrine Biosciences and Sonoma Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Sonoma Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Sonoma Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and Sonoma Pharmaceuticals, you can compare the effects of market volatilities on Neurocrine Biosciences and Sonoma Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Sonoma Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Sonoma Pharmaceuticals.

Diversification Opportunities for Neurocrine Biosciences and Sonoma Pharmaceuticals

-0.33

Correlation Coefficient

Neurocrine Biosciences  Sonoma Pharmaceuticals

Very good diversification

The 3 months correlation between Neurocrine and Sonoma is -0.33. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Sonoma Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonoma Pharmaceuticals and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Sonoma Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonoma Pharmaceuticals has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Sonoma Pharmaceuticals go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Sonoma Pharmaceuticals

Given the investment horizon of 90 days Neurocrine Biosciences is expected to generate 0.23 times more return on investment than Sonoma Pharmaceuticals. However, Neurocrine Biosciences is 4.41 times less risky than Sonoma Pharmaceuticals. It trades about 0.02 of its potential returns per unit of risk. Sonoma Pharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest  11,944  in Neurocrine Biosciences on September 20, 2024 and sell it today you would earn a total of  1,552  from holding Neurocrine Biosciences or generate 12.99% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neurocrine Biosciences  vs.  Sonoma Pharmaceuticals

Neurocrine Biosciences

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent forward indicators, Neurocrine Biosciences showed solid returns over the last few months and may actually be approaching a breakup point.

Sonoma Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sonoma Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Neurocrine Biosciences and Sonoma Pharmaceuticals

The main advantage of trading using opposite Neurocrine Biosciences and Sonoma Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Sonoma Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonoma Pharmaceuticals will offset losses from the drop in Sonoma Pharmaceuticals' long position.

The idea behind Neurocrine Biosciences and Sonoma Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..